Redeye views BONESUPPORT’s Q4 figures as positive. Despite coming in slightly under our own sales estimates (SEK 56m vs. SEK 53.2m), we are encouraged by a continued stable gross margin pushing 90% and slightly better operating profit than we anticipated (still in the negatives). We will return with a more detailed comment later today, following its conference call. Our initial take does not prompt any changes to our Base Case, we judge as of now, which stands at SEK 90 per share.